Pictet & Cie Europe SA trimmed its holdings in shares of SPDR S&P Biotech (NYSEARCA:XBI) by 27.6% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 46,390 shares of the exchange traded fund’s stock after selling 17,700 shares during the quarter. Pictet & Cie Europe SA owned 0.09% of SPDR S&P Biotech worth $4,016,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds have also made changes to their positions in the stock. Ameriprise Financial Inc. grew its stake in SPDR S&P Biotech by 0.8% during the 3rd quarter. Ameriprise Financial Inc. now owns 111,057 shares of the exchange traded fund’s stock worth $9,614,000 after buying an additional 921 shares during the last quarter. SG Americas Securities LLC grew its stake in SPDR S&P Biotech by 162.8% during the 3rd quarter. SG Americas Securities LLC now owns 303,622 shares of the exchange traded fund’s stock worth $26,285,000 after buying an additional 188,106 shares during the last quarter. Commonwealth Equity Services Inc grew its stake in SPDR S&P Biotech by 35.5% during the 3rd quarter. Commonwealth Equity Services Inc now owns 68,506 shares of the exchange traded fund’s stock worth $5,930,000 after buying an additional 17,955 shares during the last quarter. Putnam FL Investment Management Co. purchased a new position in SPDR S&P Biotech during the 3rd quarter worth $309,000. Finally, Cambridge Investment Research Advisors Inc. grew its stake in SPDR S&P Biotech by 29.8% during the 3rd quarter. Cambridge Investment Research Advisors Inc. now owns 33,982 shares of the exchange traded fund’s stock worth $2,942,000 after buying an additional 7,796 shares during the last quarter.

Shares of SPDR S&P Biotech (NYSEARCA XBI) traded up $1.38 during mid-day trading on Friday, reaching $81.43. The company had a trading volume of 3,854,700 shares, compared to its average volume of 4,235,956. SPDR S&P Biotech has a 1 year low of $58.66 and a 1 year high of $88.98.

TRADEMARK VIOLATION NOTICE: This story was first reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this story on another domain, it was illegally copied and reposted in violation of US and international trademark and copyright legislation. The correct version of this story can be accessed at https://www.thecerbatgem.com/2017/11/17/pictet-cie-europe-sa-sells-17700-shares-of-spdr-sp-biotech-xbi.html.

SPDR S&P Biotech Company Profile

SPDR S&P Biotech ETF (the Fund) seeks to closely match the returns and characteristics of the S&P Biotechnology Select Industry Index. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges.

Institutional Ownership by Quarter for SPDR S&P Biotech (NYSEARCA:XBI)

Receive News & Stock Ratings for SPDR S&P Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SPDR S&P Biotech and related stocks with our FREE daily email newsletter.